Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ANRO Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 20, 2026
Report Source: 2026 1st Quarter Report
Alto Neuroscience Inc. Stock Analysis ANRO
United States Health Care Small Cap Report: Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 68 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Read More Alto Neuroscience Inc (ANRO) Chart
Key Statistics of Alto Neuroscience Inc (ANRO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$22.32Volume
404.62KP/E Ratio (TTM)
-52 Week Range
Market Cap
755.92MAvg. Volume
348.19KDividend Yield
-Financial Metrics & Statements of Alto Neuroscience Inc (ANRO)
FAQ's for Alto Neuroscience Inc (ANRO)
- According to Musaffa’s Shariah screening methodology, Alto Neuroscience Inc (ANRO) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Alto Neuroscience Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Alto Neuroscience Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Alto Neuroscience Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Alto Neuroscience Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Alto Neuroscience Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.